Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

SIMPLE SUMMARY: PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) are widely used in metastatic melanoma. Immunotherapy leads to prolonged lymphocyte effects, which explains the cytotoxicity underlying immune-reaction-based adverse events. Most adverse events (irAEs) oc...

Descripción completa

Detalles Bibliográficos
Autores principales: L’Orphelin, Jean-Matthieu, Varey, Emilie, Khammari, Amir, Dreno, Brigitte, Dompmartin, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508100/
https://www.ncbi.nlm.nih.gov/pubmed/34638410
http://dx.doi.org/10.3390/cancers13194928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508100/
https://www.ncbi.nlm.nih.gov/pubmed/34638410
http://dx.doi.org/10.3390/cancers13194928

Ejemplares similares